Goldman Sachs Upgrades Cytokinetics (CYTK) to Buy

Goldman Sachs analyst Paul Choi upgraded Cytokinetics (NASDAQ: CYTK) from Neutral to Buy with a price target of $95.00.

The analyst comments "Learnings from ODYSSEY increase the odds of ACACIA succeeding; a series of label expansions could put aficamten in a privileged competitive position. We see CYTK as re-emerging in 2026 as one of the drivers of the cardiology renaissance (link) and poised to outperform the group given a series of near- to intermediate-term catalysts, which if positive, could reposition aficamten from a second-in-class to the preferred CMI and re-order the HCM landscape. We are more positive heading into the ACACIA-HCM results next year and think label expansion could meaningfully alter the competitive dynamics within HCM and increase CYTK's appeal to strategics interested in large TAM cardiology assets, and we thus introduce an M&A component to our valuation. Upgrade to Buy and increase 12-month PT to $95."

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $59.82 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker